Vanguard Fiduciary Trust
PTHS

Vanguard Fiduciary Trust’s Pelthos Therapeutics PTHS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$279K Buy
9,873
+56
+0.6% +$1.44K ﹤0.01% 3468
2026
Q1 		$206K Buy
+9,817
New +$233K ﹤0.01% 3514

Other funds holding PTHS

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CF
Cantor Fitzgerald New York $9.23B AUM 74.53% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
DMKJ
David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Vanguard Fiduciary Trust's PTHS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Pelthos Therapeutics (PTHS) stake by 0.57% in Q2 2026, buying an estimated $1.44K and bringing the position to 9,873 shares worth $279K. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

Vanguard Fiduciary Trust first reported a position in PTHS in Q1 2026 and has held it in 2 quarters since. 24 funds tracked by Wall St. Rank hold PTHS as of Q2 2026.

  • Vanguard Fiduciary Trust held 9,873 shares of Pelthos Therapeutics worth $279K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 56 Pelthos Therapeutics shares in Q2 2026, an estimated $1.44K.
  • Pelthos Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3468 holding.
  • Vanguard Fiduciary Trust first reported a position in Pelthos Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 24 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.